Applied Therapeutics, Inc.
APLT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $10 | $0 | $0 |
| % Growth | -95.4% | – | – | – |
| Cost of Goods Sold | $49 | $54 | $0 | $0 |
| Gross Profit | -$48 | -$44 | -$0 | $0 |
| % Margin | -10,613% | -439.4% | – | – |
| R&D Expenses | $49 | $54 | $56 | $63 |
| G&A Expenses | $55 | $20 | $27 | $43 |
| SG&A Expenses | $56 | $21 | $27 | $43 |
| Sales & Mktg Exp. | $1 | $1 | $0 | $1 |
| Other Operating Expenses | -$49 | -$54 | -$0 | $0 |
| Operating Expenses | $56 | $21 | $83 | $106 |
| Operating Income | -$104 | -$65 | -$83 | -$106 |
| % Margin | -22,922.9% | -645.8% | – | – |
| Other Income/Exp. Net | -$1 | -$55 | $0 | $0 |
| Pre-Tax Income | -$106 | -$120 | -$83 | -$106 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$106 | -$120 | -$83 | -$106 |
| % Margin | -23,214.1% | -1,198.5% | – | – |
| EPS | -0.76 | -1.42 | -2.18 | -4.12 |
| % Growth | 46.5% | 34.9% | 47.1% | – |
| EPS Diluted | -0.76 | -1.42 | -2.18 | -4.12 |
| Weighted Avg Shares Out | 140 | 84 | 38 | 26 |
| Weighted Avg Shares Out Dil | 140 | 84 | 38 | 26 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$104 | -$65 | -$82 | -$106 |
| % Margin | -22,922.6% | -645.8% | – | – |